Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 3 - You Need To See This

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Barchart

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Barchart

Are Wall Street Analysts Predicting Amgen Stock Will Climb or Sink?

Despite Amgen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks Revolutionizing Healthcare

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth. Thus, investing in fundamentally stable stocks, Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD), could be a wise way to capitalize on the industry’s growing momentum. Read more….

StockNews.com

Amgen’s Q4 2024 Earnings: What to Expect

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

Barchart

Build a Bulletproof Portfolio with These Three Diversified Dividend Stocks

Learn how diversification, careful screening, and key metrics like payout ratios and yields can help build a strong, income-generating portfolio for the long term.

Barchart

Selling Covered Calls On The Dogs Of The Dow Stocks

The Dogs of the Dow is a long standing wall street strategy for investing in the stock market that involves purchasing the 10 highest yielding Dow Jones stocks.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks With Promising Pipelines

The biotech sector’s AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on.

StockNews.com

3 Biotech Stocks Revolutionizing Cancer Treatment

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the field. Given the robust prospect, investors looking for fundamentally sound biotech stocks might consider adding Regeneron Pharmaceuticals (REGN), Amgen (AMGN), and Gilead Sciences (GILD) to their portfolio. Read on….

StockNews.com

Is Amgen Stock Underperforming the Dow?

Despite pharma giant Amgen trailing behind the Dow index over the past three months, analysts remain cautiously bullish about the stock's growth potential.

Barchart

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

Is Wall Street Bullish or Bearish on Amgen Stock?

Amgen has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

StockNews.com

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Amgen Earnings Preview: What to Expect

Amgen will release its third-quarter earnings this month, and analysts anticipate a single-digit bottom-line growth.

StockNews.com

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

Barchart

Is Amgen Stock Outperforming the Nasdaq?

Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.

Barchart

AMGN Bullish Diagonal Trade Targets a Price of $350 by October 18th

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, yet Wall Street analysts remain cautiously optimistic about the stock’s prospects.

StockNews.com

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

Barchart

What You Need to Know Ahead of Amgen's Earnings Release

Amgen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

StockNews.com

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

Barchart

Is Amgen Stock Outperforming the S&P 500?

Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.

Barchart

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

StockNews.com

3 Biotech Stocks With Potential Breakthroughs Emerging

The biotech industry's future is promising, driven by advanced technologies like AI and VR, the rising popularity of personalized treatments, and increased R&D spending. Let's analyze the investment prospects of biotech stocks Amgen (AMGN), United Therapeutics (UTHR), and Gilead Sciences (GILD) as potential breakthroughs emerge. Read more.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.